The 10 that are cited most themselves, of 33.
Judgment of the Court (Fourth Chamber), 19 July 2012. Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.Decisioninterprets
This reference for a preliminary ruling relates to the interpretation of, first, Articles 3 and 13(1) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection …
19 Jul 2012 · 62011CJ0130
Judgment of the Court (Third Chamber), 12 December 2013. Actavis Group PTC EHF and Actavis UK Ltd v Sanofi.Decision
In such a situation, Article 13 of Regulation No 469/2009 dictates that, upon expiry of the initial SPC, the holder thereof may no longer, in connection with the basic patent used as the basis for the grant of the SPC, oppose the marketing …
12 Dec 2013 · 62012CJ0443
Judgment of the Court (Eighth Chamber) of 12 March 2015. Actavis Group PTC EHF and Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. KDecision
This request for a preliminary ruling concerns the interpretation of Articles 3 and 13 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for …
12 Mar 2015 · 62013CJ0577
Judgment of the Court (Grand Chamber) of 25 July 2018. Teva UK Ltd and Others v Gilead Sciences Inc.Decision
Article 13 of that regulation, entitled ‘Duration of the [SPC]’, provides in paragraph 1 thereof as follows: ‘The [SPC] shall take effect at the end of the lawful term of the basic patent for a period equal to the period which …
25 Jul 2018 · 62017CJ0121
Judgment of the Court (Third Chamber), 12 December 2013. Georgetown University v Octrooicentrum Nederland.Decision
Moreover, Article 13 of Regulation No 469/2009 dictates that, upon expiry of such SPCs, the holder thereof may no longer, in connection with the basic patent used as the basis for the grant of those SPCs, oppose the marketing by third …
12 Dec 2013 · 62012CJ0484
The Human Medicines Regulations 201258aLaw
… medicinal product to which the application relates is entitled to a six month extension of the period referred to in Articles 13(1) and 13(3) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 …
The Human Medicines (Amendment etc.) (EU Exit) Regulations 201964Law
… medicinal product to which the application relates is entitled to a six month extension of the period referred to in Articles 13(1) and 13(3) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 …
Order of the Court (Eighth Chamber) of 14 November 2013. Astrazeneca AB v Comptroller General of Patents, Designs and Trade Marks.Decisioninterprets
On those grounds, the Court (Eighth Chamber) hereby rules: In the context of the European Economic Area (EEA), Article 13(1) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the …
14 Nov 2013 · 62012CO0617
The Human Medicines (Amendment etc.) (EU Exit) Regulations 202047Law
… medicinal product to which the application relates is entitled to a six month extension of the period referred to in Articles 13(1) and 13(3) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 …
Judgment of the Court (Grand Chamber) of 9 July 2020. Santen SAS v Directeur général de l’Institut national de la propriété industrielle.Decision
Under Article 13 of that regulation, entitled ‘Duration of the [SPC]’: ‘1. The [SPC] shall take effect at the end of the lawful term of the basic patent for a period equal to the period which elapsed between the date on which the …
9 Jul 2020 · 62018CJ0673